鹭燕医药:2025一季报净利润0.71亿 同比下降15.48%

Financial Performance - The company's basic earnings per share for Q1 2025 is 0.1800 yuan, a decrease of 18.18% compared to Q1 2024, which was 0.2200 yuan [1] - The net profit for Q1 2025 is 0.71 billion yuan, down 15.48% from 0.84 billion yuan in Q1 2024 [1] - The return on equity (ROE) for Q1 2025 is 2.23%, a decline of 20.36% from 2.80% in Q1 2024 [1] - The total revenue for Q1 2025 is 51.74 billion yuan, showing a slight increase of 0.74% from 51.36 billion yuan in Q1 2024 [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 15,797.43 million shares, accounting for 41.39% of the circulating shares, with a decrease of 126.77 million shares compared to the previous period [2] - Xiamen Maidi Ken Technology Co., Ltd. remains the largest shareholder with 13,803.07 million shares, representing 36.17% of the total share capital [2] - New entrants in the top ten shareholders include China Merchants Fund Management Co., Ltd. - Social Security Fund 1903 Portfolio and Chen Feng, holding 165.77 million shares (0.43%) and 145.00 million shares (0.38%) respectively [2] Dividend Policy - The company has announced that it will not distribute dividends or transfer shares this time [3]